63837-12-7

Basic information

• Product Name: 5-AMINOBENZOOXAZOLE
• Synonyms: 5-AMINOBENZOOXAZOLE ;Benzooxazol-5-ylamine;5-Aminobenzoxazol;benzo[d]oxazol-5-aMine;1,3-Benzoxazol-5-amine, 5-Aminobenzo[d]oxazole;1,3-Benzoxazol-5-aMine, >95%
• CAS NO: 63837-12-7
• Molecular Formula: C₇H₆N₂O
• Molecular Weight: 134.13534
• Product Categories: Amines;Oxazoles, Isoxazoles & Benzoxazoles;Oxazoles, Isoxazoles & Benzoxazoles
• Mol File: 63837-12-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 64-66°C
• Boiling Point: 282.3°C at 760 mmHg
• Flash Point: 124.5°C
• Appearance: /
• Density: 1.317g/cm³
• Vapor Pressure: 0.00339mmHg at 25°C
• Refractive Index: 1.685
• PKA: 6.97±0.10(Predicted)
• CAS DataBase Reference: 5-AMINOBENZOOXAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINOBENZOOXAZOLE(63837-12-7)
• EPA Substance Registry System: 5-AMINOBENZOOXAZOLE(63837-12-7)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 63837-12-7(Hazardous Substances Data)

Usage

General Description

5-Aminobenzooxazole is a chemical compound with the molecular formula C7H7N3O. It is classified as an aminobenzooxazole and is used in various industrial applications, including the production of pharmaceuticals and organic synthesis. It is a yellowish crystalline powder that is insoluble in water but soluble in organic solvents. 5-Aminobenzooxazole is also used as a building block in the synthesis of biologically active molecules and pharmaceuticals. It has potential uses in the field of medicine and biochemistry due to its ability to interact with biological systems and its structural properties.

InChI:InChI=1/C7H6N2O/c8-5-1-2-7-6(3-5)9-4-10-7/h1-4H,8H2

Upstream product

• 99-57-0 2-hydroxy-5-nitroaniline 
• 70886-33-8 5-nitro-benzooxazole 

Downstream Products

• 1620292-42-3 phenyl benzo[d]oxazol-5-ylcarbamate 

Relevant articles and documents

ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I' PATHWAY AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN

The present invention relates to compounds according to Formula 1 and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.

Vanilloid receptor ligands and their use in treatments

Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.